United States

Home / Products / Cats & Dogs / Apoquel

Print page content Print
Increase text size Decrease text size
Text Size
GO TO PET OWNER SITE
When it comes to fast relief from allergic itch without steroid side effects,
IT WOULD
BE A SHAME
TO MAKE
THEM WAIT
When it comes to fast relief from allergic itch without steroid side effects,
IT WOULD
BE A SHAME
TO MAKE
THEM WAIT

FIRST TIME, EVERY TIME

Start and stay with APOQUEL for relief of short- and long-term allergic itch.1-4

VIEW EFFICACY

Fast and Effective

  • Starts working in 4 hours1
  • Controls itch within 24 hours2

Safety

  • Not a steroid
    • Free from many steroid-associated side effects2
  • Can be used with many other drugs
    • Including NSAIDs, anti-infectives, parasiticides, antifungals and allergen-specific immunotherapy3
  • Safe for long-term use4

Allows Diagnostic Testing

  • Does not interfere with testing or diagnostics5
  • Fast relief restores quality of life while you determine the cause of itch3

"It was like seeing her find herself again!"
— Bijou's owner, 11/10/16

SEE MORE APOQUEL SUCCESS STORIES

Important Safety Information
Do not use APOQUEL® (oclacitinib tablet) in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.

For more information, please see the full Prescribing Information.

References: 1. Gadeyne C, Little P, King VL, et al. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014;25(6):512-518. doi:10.1111/vde.12166. 2. Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013;24(5):479-e114. doi:10.1111/vde.12047. 3. Cosgrove SB, Cleaver DM, King VL, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol. 2015;26(3):171-179. doi:10.1111/vde.12194. 4. Data on file, Study Report 1962R-60-11-A75, Zoetis, Inc. 5. Aleo MM, Galvan EA, Fleck JT, et al. Effects of oclacitinib and prednisolone on skin test sensitivity [abstract]. Vet Dermatol. 2013;24(3):297. 6. Data on file, Pet Owner Case Studies–Bijou, Gunner, Nani, Captain and Molly, Zoetis Inc.

APOQUEL gives dogs fast, effective allergic itch relief

Proven efficacy for allergic skin diseases

Proven efficacy for allergic skin diseases

Effective in flea allergy, food allergy, contact allergy, atopic dermatitis1,2

APOQUEL gives dogs fast, effective allergic itch relief

Proven efficacy for allergic skin diseases

Effective in flea allergy, food allergy, contact allergy, atopic dermatitis1,2

Proven efficacy for allergic skin diseases

APOQUEL delivered fast relief that began to control itch within 4 hours, comparable to oral steroids3,4

Apoquel delivered fast relief vs steroids

Inclusion Criteria
Study design

APOQUEL exhibited faster onset of relief than Atopica® (cyclosporine capsules, USP) in the control of pruritus in dogs with atopic dermatitis5,6

Apoquel delivered fast relief vs Atopica

Inclusion Criteria
Study design

APOQUEL lets you establish and maintain itch relief while allowing you to complete diagnosis

  • Short half-life lets you “turn on” and “turn off” itch control for food trial assessment and flea control
Relieve itch with APOQUEL during an 8-week food trial9
APOQUEL during an 8-week food trial

Works differently from steroids and cyclosporine

  • Nonsteroidal APOQUEL targets specific cytokines that cause itch and inflammation, relieving symptoms of allergic skin disease with minimal impact on the immune system10

Cytokines involved in dog allergies

APOQUEL inhibits the function of a variety of pruritogenic and proinflammatory cytokines, including JAK1- and JAK3-dependent cytokines involved in dog allergies…

Apoquel controls itch with minimal immune effect

…while having only minimal effect on JAK2-dependent cytokines involved in hematopoiesis and innate immunity

Learn more about the cycle of itch and how APOQUEL interrupts it.

The Itch Cycle

APOQUEL is one of 2 excellent choices for long-term control of atopic dermatitis — learn more about the options

Dermatology Portfolio

Important Safety Information
Do not use APOQUEL® (oclacitinib tablet) in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.

For more information, please see the full Prescribing Information.

References: 1. Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013;24(5):479-e114. doi:10.1111/vde.12047. 2. Moriello KA. Canine allergic dermatitis: pathogenesis, clinical signs, and diagnosis. http://veterinarymedicine.dvm360.com/canine-allergic-dermatitis-pathogenesis-clinical-signs-and-diagnosis. Accessed August 22, 2017. 3. Gadeyne C, Little P, King VL, et al. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014;25(6):512-518. doi:10.1111/vde.12166. 4. Data on file, Study Report No. A161R-AU-12-096, Zoetis Inc. 5. Little PR, King VL, Davis KR, et al. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and cyclosporine for the control of atopic dermatitis in client-owned dogs. Vet Dermatol. 2015;26(1):23-30. doi:10.1111/vde.12186. 6. Data on file, Study Report No. 6962R-14-10-025, Zoetis Inc. 7. Data on file, Study Report No. 1962C-60-10-A16, Zoetis Inc. 8. Cosgrove SB, Wren JA, Cleaver DM, et al. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis. Vet Dermatol. 2013;24(6):587-597. doi:10.1111/vde.12088. 9. Olivry T, Mueller R, Prélaud P, et al. Critically appraised topic on adverse food reactions of companion animals (1): duration of elimination diets. BMC Vet Res. 2015;11:225. doi:10.1186/s12917-015-0541-3. 10. Gonzales AJ, Bowman J, Fici G, et al. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014;37(4):317-324. doi:10.1111/jvp.12101.

How to dose APOQUEL

  • The dose of APOQUEL tablets is 0.18 to 0.27 mg/lb (0.4 to 0.6 mg/kg)
  • APOQUEL should be given twice daily (BID) for up to 14 days of therapy and once daily (SID) thereafter for maintenance
  • APOQUEL may be given with or without food
  • APOQUEL may be discontinued without tapering
Apoquel dose chart

Important Safety Information
Do not use APOQUEL® (oclacitinib tablet) in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.

For more information, please see the full Prescribing Information.

Fast, safe relief for short- and long-term pruritus — first time, every time

Minimal side effects

  • Side effects were similar to placebo1
  • Does not cause many of the side effects associated with steroids1

Can be used concomitantly with many medications

  • Including NSAIDs, anti-infectives, parasiticides, antifungals and allergen-specific immunotherapy2

Allows you to complete diagnostic workup

  • Fast itch control improves quality of life while you diagnose3
  • Short half-life lets you “turn on” and “turn off” itch control for food trial assessment and flea control

Safe for long-term use

  • Minimal side effects were reported by owners whose dogs received APOQUEL for up to 22 months2
  • Results from a pre-approval, observational continuation study2

Important Safety Information
Do not use APOQUEL® (oclacitinib tablet) in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.

For more information, please see the full Prescribing Information.

References: 1. Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013;24(5):479-e114. doi:10.1111/vde.12047. 2. Cosgrove SB, Cleaver DM, King VL, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol. 2015;26(3):171-179. doi:10.1111/vde.12194. 3. Aleo MM, Galvan EA, Fleck JT, et al. Effects of oclacitinib and prednisolone on skin test sensitivity [abstract]. Vet Dermatol. 2013;24(3):297. 4. Data on file, Study Report No. A161R-AU-12-096, Zoetis Inc. 5. Cosgrove SB, Wren JA, Cleaver DM, et al. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis. Vet Dermatol. 2013;24(6):587-597. doi:10.1111/vde.12088. 6. Data on file, Study Report No. 6962R-14-10-025, Zoetis Inc. 7. Little PR, King VL, Davis KR, et al. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and cyclosporine for the control of atopic dermatitis in client-owned dogs. Vet Dermatol. 2015;26(1):23-30. doi:10.1111/vde.12186. 8. Gadeyne C, Little P, King VL, et al. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014;25(6):512-518. doi:10.1111/vde.12166.

APOQUEL has changed the lives of dogs and their owners!

NANI suffered from a grass allergy1
Apoquel (oclacitinib) relieved Nani’s dog allergiesApoquel (oclacitinib) relieved Nani’s dog allergies
NANI suffered from a grass allergy1

[Now Nani] can sleep at night, She can go outside and play. She has a better quality of life.

– Nani's owner, 11/10/16
GUNNER had itching and an infected hot spot1
Apoquel (oclacitinib) relieved Gunner’s dog allergiesApoquel (oclacitinib) relieved Gunner’s dog allergies
GUNNER had itching and an infected hot spot1

Once I left the clinic knowing that the injection of CONVENIA and the APOQUEL were on board initially, and I saw the relief in Gunner, I felt relief myself.

– Gunner's owner, 11/10/16
CAPTAIN did not do well on steroids1
Captain’s owner shares Apoquel reviewCaptain’s owner shares Apoquel review
CAPTAIN did not do well on steroids1

Within a week he had his cone off and he looked like a normal dog!

– Captain's owner, 12/10/13
MOLLY struggled with multiple allergies1
Molly’s owner shares Apoquel reviewsMolly’s owner shares Apoquel reviews
MOLLY struggled with multiple allergies1

[Now] she just has such a different personality… Or maybe she had that personality and it was just masked by all the pain and the suffering before.

– Molly's owner, 12/10/13

Pet owners love APOQUEL too!

Owners of allergic dogs were asked for their APOQUEL reviews2:

90% would recommend APOQUEL to a friend

96% believed APOQUEL improved the quality of their dog’s life

94% said APOQUEL improved the quality of their own life

Important Safety Information
Do not use APOQUEL® (oclacitinib tablet) in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.

For more information, please see the full Prescribing Information.

References: 1. Data on file, Pet Owner Case Studies–Nani, Gunner, Captain and Molly, Zoetis Inc. 2. Data on file, APOQUEL EEP Pet Owner Aggregate Data, Zoetis Inc.

The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional.  Testimonials represent individual experience only and the experiences and opinions herein may be unique to the patient and the speaker.  Individual results may vary considering the unique characteristics of the patient.

APOQUEL resources

Clinical information

APOQUEL technical monograph

A comprehensive overview of allergic skin disease and APOQUEL, including pharmacology and clinical trials.

Steroid side effects 1-pager

A simple diagram that reviews short-term and long-term side effects of steroids.

Promotional materials for your practice

Waiting room video

A colorful and compelling 60-second video introduction to APOQUEL. Video is subtitled so it can be played without sound.

Client information sheet

Gives dog owners a quick overview of allergic skin disease and a review of APOQUEL treatment explaining what to expect.

Itch tracker

Helps your clients track the improvement in their dog’s itch. 

Pet owner brochure

An informative, easy-to-understand review of APOQUEL for your customers. It can be used in the waiting room and/or given to owners whose allergic dogs have already been prescribed APOQUEL. 

Indications
Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

Important Safety Information
Do not use APOQUEL® (oclacitinib tablet) in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.

For more information, please see the full Prescribing Information.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.

© 2018 Zoetis Services LLC. All rights reserved. APQ-00371R1